Immatics N.V. (FRA:4A3)

Market Cap	1.08B +61.6%
Revenue (ttm)	84.76M -26.6%
Net Income	-119.99M
EPS	-0.99
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	811
Open	8.23
Previous Close	8.09
Day's Range	8.23 - 8.23
52-Week Range	3.08 - 10.07
Beta	n/a
RSI	41.59
Earnings Date	Mar 24, 2026

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Harpreet Singh
• Employees: 645
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4A3